PMID- 20196185
OWN - NLM
STAT- MEDLINE
DCOM- 20100614
LR  - 20220318
IS  - 1099-1077 (Electronic)
IS  - 0885-6222 (Linking)
VI  - 25
IP  - 2
DP  - 2010 Mar
TI  - Safety and tolerability of once-daily extended release quetiapine fumarate in 
      acute schizophrenia: pooled data from randomised, double-blind, 
      placebo-controlled studies.
PG  - 103-15
LID - 10.1002/hup.1091 [doi]
AB  - INTRODUCTION: Extended release quetiapine fumarate (quetiapine XR) is a new 
      formulation that allows once-daily dosing and a titration regimen that is simpler 
      than that of immediate release quetiapine (quetiapine IR) and may potentially 
      increase patients' adherence to their prescribed medication. METHODS: The 
      tolerability of quetiapine XR was examined in an analysis of pooled data from 
      three Phase III, double-blind, placebo-controlled, randomised studies with 
      quetiapine IR as a reference treatment. RESULTS: The overall incidence of adverse 
      events (AEs) was similar for quetiapine XR (69.5%) and quetiapine IR (72.5%). 
      Most AEs were mild to moderate in severity and in line with those observed with 
      quetiapine IR. The more rapid dose titration of quetiapine XR did not produce any 
      new safety concerns and was as well tolerated as the regimen for quetiapine IR. 
      CONCLUSIONS: The results of this pooled analysis show that quetiapine XR 
      administered once daily is generally as well tolerated as quetiapine IR given 
      twice daily. These data, together with the simpler dose-titration of quetiapine 
      XR that allowed therapeutically effective doses to be reached by Day 2, suggest 
      that this formulation potentially may improve adherence in patients with 
      schizophrenia.
CI  - Copyright 2010 John Wiley & Sons, Ltd.
FAU - Meulien, Didier
AU  - Meulien D
AD  - AstraZeneca Research & Development, Sodertalje, Sweden.
FAU - Huizar, Karin
AU  - Huizar K
FAU - Brecher, Martin
AU  - Brecher M
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - England
TA  - Hum Psychopharmacol
JT  - Human psychopharmacology
JID - 8702539
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Dibenzothiazepines)
RN  - 2S3PL1B6UJ (Quetiapine Fumarate)
SB  - IM
MH  - Acute Disease
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antipsychotic Agents/administration & dosage/*adverse effects/therapeutic use
MH  - Clinical Trials, Phase III as Topic
MH  - Delayed-Action Preparations/administration & dosage/adverse effects/therapeutic 
      use
MH  - Diagnostic and Statistical Manual of Mental Disorders
MH  - Dibenzothiazepines/administration & dosage/*adverse effects/therapeutic use
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multicenter Studies as Topic
MH  - Neutropenia/chemically induced
MH  - Quetiapine Fumarate
MH  - Randomized Controlled Trials as Topic
MH  - Schizophrenia/*drug therapy
MH  - Young Adult
EDAT- 2010/03/03 06:00
MHDA- 2010/06/15 06:00
CRDT- 2010/03/03 06:00
PHST- 2010/03/03 06:00 [entrez]
PHST- 2010/03/03 06:00 [pubmed]
PHST- 2010/06/15 06:00 [medline]
AID - 10.1002/hup.1091 [doi]
PST - ppublish
SO  - Hum Psychopharmacol. 2010 Mar;25(2):103-15. doi: 10.1002/hup.1091.